RegisterLogin

Deracoxib-d4

CAT: 0804-HY-W703540Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-W703540Size:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Deracoxib-d4 (SC 046-d4; SC 59046--d4) is deuterium labeled Deracoxib (HY-17509) . Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.
CAS Number
[1794780-24-7]
Product Name Alternative
SC 046-d4; SC 46-d4; SC 59046-d4
UNSPSC
12352005
Target
Apoptosis; COX; Isotope-Labeled Compounds
Related Pathways
Apoptosis; Immunology/Inflammation; Others
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease
Smiles
[2H]C1=C([2H])C(S(=O)(N)=O)=C([2H])C([2H])=C1N2C(C3=CC(F)=C(OC)C=C3)=CC(C(F)F)=N2
Molecular Formula
C17H10D4F3N3O3S
Molecular Weight
401.40
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Royals, S.R., et al., Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res, 2005. 66 (11) : p. 1961-7.|[3]Ustun Alkan, F., et al., The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal, 2012. 2012: p. 976740.|[4]Bienhoff, S.E., et al., Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg, 2012. 41 (3) : p. 336-44.|[5]McMillan, S.K., et al., Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc, 2011. 239 (8) : p. 1084-9.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-17509-01Deracoxib
HY-17509S-01Deracoxib-d3
HY-17509R-01Deracoxib (Standard)
HY-151912S-01Picolinafen-d4 (4-Fluorophenyl-d4)
HY-W654154Dexmedetomidine-d4 L-tartrate (-d4-major)
HY-151892SGlimepiride-d4 (phenylethyl-α, α, β, β-d4) (cis/trans)
HY-151910S(±) -Fluoxetine-d4 Oxalate (trifluoromethylphen-d4-oxy)
HY-132468SKeto Pioglitazone-d4 (M-III-d4)
HY-78726S-01Fosamprenavir-d4
HY-B1014S1-01Acenocoumarol-d4

Alternative Products

CatalogName
TRC-D281922-25MGDeracoxib-d4
TRC-D281920-100MGDeracoxib
A18077-500Deracoxib 500mg
A18077-50Deracoxib 50mg
A18077-25Deracoxib 25mg
A18077-100Deracoxib 100mg
A18077-200Deracoxib 200mg
A18077-10mM-DDeracoxib 10mM * 1mL in DMSO
TRC-P469996-10MG(±)-Pioglitazone-d4 (phenyl-d4)
TRC-C375251-10MG(±)-Chlorophacinone-d4 (indanedione-d4)

Popular Products